CCC
IBB icon

Crescent Capital Consulting’s iShares Biotechnology ETF IBB Stock Holding History

Crescent Capital Consulting’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$5.82M Buy
38,102
+2,895
+8% +$448K 0.96% 29
2021
Q3 		$5.69M Buy
35,207
+8,665
+33% +$1.46M 1.04% 23
2021
Q2 		$4.34M Buy
26,542
+3,325
+14% +$512K 0.81% 33
2021
Q1 		$3.49M Buy
23,217
+3,349
+17% +$532K 0.77% 38
2020
Q4 		$3.01M Buy
+19,868
New +$2.84M 0.78% 32

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Crescent Capital Consulting's IBB Position: Q4 2021 in Review

Crescent Capital Consulting increased its iShares Biotechnology ETF (IBB) stake by 8.2% in Q4 2021, buying an estimated $448K and bringing the position to 38,102 shares worth $5.82M. The position accounts for 0.96% of the portfolio, ranked #29.

Crescent Capital Consulting first reported a position in IBB in Q4 2020 and has held it in 5 quarters since. 962 funds tracked by Wall St. Rank hold IBB as of Q4 2021.

  • Crescent Capital Consulting held 38,102 shares of iShares Biotechnology ETF worth $5.82M as of Q4 2021.
  • Crescent Capital Consulting bought 2,895 iShares Biotechnology ETF shares in Q4 2021, an estimated $448K.
  • iShares Biotechnology ETF made up 0.96% of Crescent Capital Consulting's portfolio in Q4 2021, its #29 holding.
  • Crescent Capital Consulting first reported a position in iShares Biotechnology ETF in Q4 2020 and has held it in 5 quarters since.
  • 962 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2021.

Based on Crescent Capital Consulting's 13F filing for Q4 2021, filed 18 Jan 2022.